Request for Service: Pulse Field Ablation Comparative Assessment Development

The U.S. Food and Drug Administration’s Office of Acquisitions and Grants Services, under the Department of Health and Human Services, has issued a solicitation for the development of a comparative assessment of pulse field ablation technologies. This is a total small business set-aside contracting opportunity designated under FAR 19.5, exclusively available to small businesses as defined by the Small Business Administration. The solicitation, identified as SB134042, was posted on July 7, 2026, with questions due by 10 AM EST on July 10, 2026, and proposals must be submitted no later than 10 AM EST on July 20, 2026. The contract falls under NAICS code 541714, which covers research and development in the physical, engineering, and life sciences. The work is to be performed in Rockville, Maryland, and all inquiries and submissions should be directed to Telisha Wilson at telisha.wilson@fda.hhs.gov. The contract aims to advance comparative evaluation methodologies for pulse field ablation systems, supporting regulatory science objectives within the FDA’s mission.